Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
Risk-stratification technology is evolving in chronic lymphocytic leukemia and can be used to guide treatment decisions and direct patients to clinical trials.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
